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SUMMARY Prurigo nodularis (PN) is a benign neurodermatitis of 
unknown etiology characterized by firm, hyperkeratotic pruritic nodules 
most commonly localized symmetrically on the bilateral extensor 
lower extremities. PN represents a primary dermatological condition 
or a dermatological manifestation of repeated traumatic manipulation 
secondary to chronic pruritus. One must consider underlying causes of 
pruritus, which may include psychiatric disorders and internal disease. 
Given its chronicity and relapsing nature, treatment of PN can be 
challenging. Interruption of the itch-scratch cycle is difficult; long term 
prognosis remains guarded. 
KEY WORDS: prurigo nodularis, neurodermatitis, neurohyperplasia, 
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INTRODUCTION
 Prurigo nodularis (PN), first described by Hard-
away in 1880 and named by Hyde and Montgom-
ery (1) in 1909, is a chronic, benign neurodermati-
tis of unclear etiology characterized by excoriated, 
intensely pruritic nodules, which are secondary 
to an intense itch-scratch cycle. It is found mostly 
on exposed extensor skin surfaces of the lower 
extremities. After vigorous scratching or rubbing, 
cutaneous manifestations may include lichenifica-
tion, neurotic excoriations and ultimately nodula-
tion, PN. Postinflammatory hypopigmentation or 
hyperpigmentation can also result, often central 
hypopigmentation highlighted by border hyperpig-
mentation.  Recently, the International Forum for 
the Study of Itch proposed a classification of the 
various diseases that present with itch as a means 
of facilitating diagnosis and improving treatment 
modalities and outcomes. PN falls under group III, 
which encompasses chronic secondary scratch 
lesions (2). There are three types of PN (Table 1). 
Recent advances have been made in treatment; 
however, much remains to be done. 
 Many conditions may trigger PN, such as arthro-
pod bite reactions, psychiatric illness, and systemic 
disease, including internal malignancy (Table 2); 
however, a direct causal link has yet to be found. It 
has been postulated that nerve growth factor (NGF), 
substance P, and various other neuropeptides as 
well as mast cells and eosinophils are involved in 
the inflammatory and pruritic response of skin in PN 
(3). The mainstay of treatment for intense pruritus 
should initially be to detect and subsequently treat 
any underlying cause. However, this daunting task 
is usually unaccomplished, and symptomatic relief 
remains the only option. Unfortunately, chronic pru-
ritus in general and prurigo nodularis specifically 
are difficult to treat. Topical and intralesional cor-
ticosteroids, calcipotriol, capsaicin, narrow-band 
UVB, thalidomide, and cyclosporine (4) have been 
used with only limited success.
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Table 2. Conditions associated with prurigo nodu-
laris







- Iron deficiency anemia
- Chronic renal failure
- Chronic liver disease (hepatitis B and C, α-1  
  antitrypsin deficiency, primary biliary cirrhosis,  
  primary sclerosing cholangitis, other cirrhotic  
  conditions)
- Human immunodeficiency virus
- Manifestation of underlying renal/hepatic/ 





 As initially described by Hyde and Montgomery 
(1), PN most commonly affects the middle-aged 
and elderly, although it has been seen in young 
men and children as well (5). Classically, two 
forms of PN are often delineated: atopic PN and 
non-atopic PN (6). Atopic PN has an earlier onset 
and seems to be associated with atopic dermatitis, 
while simultaneously displaying hypersensitivity to 
various environmental allergens. Non-atopic PN, 
in contrast, has an older age of onset and lacks 
a cutaneous response to allergens.  Among our 
patients, we have distinguished a third form that 
is associated with human immunodeficiency virus 
(HIV) disease (Table 1).     
 PN may be viewed as a hyperplastic form of li-
chen simplex chronicus (6). There is no racial or 
sexual predilection for PN, and no increase in mor-
tality other than that associated with the underlying 
cause (7). Importantly, psychosocial morbidity of 
chronic, unrelenting, intense pruritus may be sig-
nificantly damaging to one’s quality of life (8).
HISTOpATHOlOgY
  Microscopically, a typical PN nodule may show 
hypertrophy of cutaneous nerves in the dermis 
(9,10). It has further been demonstrated that der-
mal nerves display an inclination towards neuro-
nal hyperplasia (11). Interestingly, PN also shares 
some features with both psoriasis and ichthyosis 
as it demonstrates parakeratotoic hyperkeratosis 
accompanied by acanthosis and papillomatosis. 
Rete ridge elongation with a dense dermal lym-
phohistiocytic infiltrate may also be evident (7). 
Epidermal changes are most typical while neu-
ronal changes are neither commonly evident nor 
required for diagnosis. Using electron microscopy, 
one can see nerve fibers thickened and dilated 
with hyperproliferation of Schwann cells and ax-
ons along with vacuolization and degeneration of 
Schwann cells including disruption of internal or-
ganelle architecture (10).   
ETIOlOgY AND pATHOgENESIS
 PN has generated many theories as to its 
pathogenesis. Emotional stress may contribute to 
PN in some patients, especially those classified as 
compulsive “pickers” (12). Depression and anxiety 
maintain a close association (13). In patients with 
chronic kidney disease, imbalances in levels and 
accumulation of calcium, phosphorus, magnesium, 
and aluminum, especially in hemodialysis patients, 
can be a significant cause of pruritus (3). Viral in-
fection with subsequent immune complex depo-
sition in the skin has also been implicated in PN 
pathogenesis, most commonly with chronic hepati-
tis B (14), hepatitis C (15) and HIV (16) infections.  
 Mast cells, eosinophils, neutrophils, and various 
component proteins and substances have been 
studied to ascertain their role in the pathogenesis 
of PN. Mast cells not only increase in number, but 
also show changes in morphology, such as an en-
larged cell body and a more dendritic shape com-
pared to that in normal skin (17). There is no sig-
nificant increase in the concentration of mast cell 
tryptase or neutrophil elastase in the surrounding 
tissue (10). A key culprit detected in diagnostic 
skin biopsies of PN is the increased concentra-
tion of eosinophil degranulation products, such as 
eosinophil granule major basic protein, eosinophil 
cationic protein, and eosinophil-derived neurotox-
in, which all have potent ability to damage nerves 
and exacerbate inflammation (10,17). Interesting-
ly, increased circulating and infiltrating eosinophils 
in conjunction with their component proteins are 
also implicated in symptomatic atopic dermatitis 
(18).  
 Mast cells have also been implicated in the 
pathogenesis of PN through a NGF: nerve growth 
Table 1. Forms of prurigo
- Atopic prurigo nodularis
- HIV-associated prurigo nodularis
- Non-atopic non-HIV linked prurigo nodularis
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factor receptor (NGFr) mechanism. Mast cells are 
known to release NGF. With increased mast cells 
in PN, there is enhanced NGF expression, which 
may produce neurohyperplasia (19). In normal 
skin, there is weak immunoreactive epidermal and 
dermal staining for NGF and p75 NGFr. In con-
trast, both are overexpressed in Schwann cells 
and perineurium cells in hyperplastic PN nerves, 
facilitating the neurohyperplasia seen in this dis-
ease (20,21).
 Other skin findings thought to be involved in the 
pathogenesis of PN include an increase in both 
epidermal Merkel cells (22) and dermal Langer-
hans cells (23).  
ClINICAl fEATURES AND 
SIgNIfICANCE
 Pruritic processes may be first evident in a 
manner consistent with either a primary dermato-
logical condition or as a secondary manifestation 
of an internal disease. Prurigo, from the Latin pru-
rire –“to itch”, is a generalized term that describes 
intensely pruritic cutaneous changes of unknown 
etiology that are characterized by focal excoria-
tions and distinctive pigmentary alterations when 
healed. After a perpetual itch-scratch cycle has 
been established, lichenification of the skin may 
ensue, resulting in a chronic dermatitis termed li-
chen simplex chronicus. There are various sub-
types of prurigo, of which PN is one. 
 In a PN patient with chronic pruritus, a com-
prehensive history and thorough physical exami-
nation are crucial. Underlying causes may include 
significant internal pathology such as liver or kid-
ney disease, leukemia, lymphoma, or other ma-
lignancy (Table 2). Physical examination should 
carefully assess for jaundice and other signs of 
liver disease, hyper- or hypothyroidism, lymph-
adenopathy, infectious etiologies, xerosis, or other 
abnormalities of the hair, nails, or mucous mem-
branes. Nodular scabies should be considered 
(24). Neurodermatitis without prurigo nodules may 
represent dermatitis herpetiformis, pemphigus 
nodularis, and linear IgA bullous dermatitis. 
 PN is characterized by several to hundreds 
of hyperkeratotic, excoriated, pruritic papules or 
nodules with a tendency for symmetric distribution 
over the extensor surfaces of extremities. They 
can vary in size from 2-3 mm to 2 cm in diam-
eter, appearing well demarcated, firm, scaly, and 
hyperpigmented or purpuric (Fig. 1) (7). In gen-
eral, PN has been described on all parts of the 
body. The palms and soles are rarely affected 
(13). The mid-back may be spared because it 
may be difficult to reach, a pattern known as the 
“butterfly sign” (12). The nodular pattern may be 
follicular or linear while the skin in-between may 
be lichenified or xerotic (Fig. 2) (13). In contrast, 
patients with neurodermatitis lack the nodular pat-
tern but still demonstrate significant excoriation, 
lichenification and xerosis (Fig. 3). In our experi-
ence, patients are usually frustrated, often stat-
ing that pruritus prevents them from adequately 
performing their daily activities. Furthermore, the 
figure 1. Multiple, excoriated, hyperkeratotic nod-
ules with areas of post-inflammatory hyperpig-
mentation. figure 2. Solitary hyperkeratotic nodule (bottom) and hyperkeratotic plaque (top) with adjacent li-
chenification.
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relentless itching with frequently unsuccessful 
treatment is often experienced by patients as loss 
of control, associated learned helplessness, and 
loss of faith in treatment modalities. In one study, 
psychiatric disorders such as dysthymia, major 
depressive disorder, or adjustment disorder were 
significantly associated with intensity as opposed 
to duration of the itch (8).
 In a retrospective analysis of PN patients, a link 
was identified between PN and psychosocial and 
metabolic disorders, specifically diabetes mellitus, 
which was present in 17% of patients (25). Anoth-
er series of 46 PN patients identified an underlying 
metabolic disorder in 50% of them (13). Further-
more, 65% to 80% of PN patients may be atopic 
and have associated xerosis. Interestingly, the 
possibility of infection with Helicobacter pylori has 
also been recently proposed as a distinct cause of 
pruritus that may lead to PN (12). 
DIffERENTIAl DIAgNOSIS
 The differential diagnoses are delineated in 
Table 3. Pemphigus nodularis, hypertrophic li-
chen planus, mycosis fungoides and nodular sca-
bies are the inflammatory conditions most closely 
linked. 
Treatment and follow up
 PN represents a therapeutic challenge distinct 
from the management of prurigo. Patients with 
PN should be encouraged not to pick, scratch, or 
rub nodules, as symptoms tend to intensify with 
repeated manipulation. Patients should use mois-
turizers to prevent or treat xerosis, which may ex-
acerbate pruritus. When assessing a patient with 
PN, it is important to search for the underlying 
cause. If one is detected, treatment should be tar-
geted towards the specific disorder with referrals 
made as deemed medically necessary.  
 If the underlying cause is not detected, which 
is most likely the case, treatment remains symp-
tomatic. Initial therapy should consist of a medium 
to high potency topical steroid applied twice daily 
for several weeks, often used in conjunction with 
an occlusive tape to enhance penetration and pro-
tect against scratching. Alternatively, intralesional 
corticosteroids may be administered every four 
to six weeks. Cordran tape™ does an excellent 
job for selected nodules in our experience. Topi-
cal antipruritics such as 1% menthol or phenol in 
a cream base, pramoxine with hydrocortisone, or 
Sarna™ lotion may aid in symptom control (3,26). 
Sedating antihistamines such as hydroxyzine and 
promethazine at bedtime may also be important 
in therapeutic improvement of the patient’s quality 
of life. In our patient population, chlorpheniramine 
maleate 4 mg, one to two tablets every night at 
bedtime as needed, shows promise. Selective se-
rotonin reuptake inhibitors and other antidepres-
sants may also be beneficial in relieving the ob-
sessive nature of PN as well as any associated 
depression. Psychiatric referral may help patients 
with associated depression or anxiety.
 We sometimes use cryosurgery and UV light 
therapy, both of which have also been success-
fully employed by others in the treatment of PN. 
UV light seems to interrupt the itch-scratch cycle, 
while cryosurgery is thought to ablate peripheral 
sensory nerves. Two to four 30-second thaw cy-
cles can render patients asymptomatic for a few 
months (7). Furthermore, the post-treatment in-
flammation induced by liquid nitrogen cryotherapy 
is synergistic to intralesional corticosteroid injec-
tion (3).  
 One prospective, randomized, double-blind, 
right/left comparative study evaluated the efficacy 
and safety of 50 µg/g calcipotriol ointment ap-
plied twice daily with that of 0.1% betamethasone 
figure 3. A 33-year-old male schizophrenic with 
neurotic excoriations and marked lichenification 
and xerosis of his upper back and neck. 
Table 3. Differential diagnosis of prurigo nodularis
- Pemphigus nodularis
- Hypertrophic lichen planus
- Nodular scabies
- Keratoacanthomas
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valerate ointment applied twice daily in the treat-
ment of PN (27). Patients who had multiple, per-
sistent nodules of greater than 5 mm in diameter 
on bilateral lower extremities were chosen for the 
study. All had used high potency topical corticoste-
roids, and most had previously tried intralesional 
steroids. Treatment consisting of either calcipot-
riol or betamethasone valerate was randomly as-
signed to nodules on opposite sides of the leg after 
a 4-week washout period with an emollient. Re-
sults showed a statistically significant reduction in 
the number of nodules (p<0.5) after 2 weeks with 
calcipotriol as opposed to 4 weeks with betameth-
asone valerate. A statistically significant reduction 
in the size of nodules was accomplished in both 
calcipotriol treatment arm (p<0.1) and betametha-
sone valerate arm (p<0.5) after 2 weeks; however, 
percent change in size favored calcipotriol after 
4- and 8-week intervals. It suggested calcipotriol, 
with its effect on epidermal differentiation and pro-
liferation, is safer and more efficacious than be-
tamethasone valerate ointment in the treatment 
of PN.    
 Recently, topical capsaicin has also been 
shown to reduce the number and symptoms of 
prurigo nodules (28). Acting via a vanilloid recep-
tor on free nerve endings, repeated topical appli-
cation releases and prevents accumulation of vari-
ous neuropeptides in C-type and Aδ-type nerves, 
thereby blocking pain and pruritic sensation while 
keeping tactile stimulation intact (3). In one study, 
the application of topical capsaicin (0.025% to 
0.3%) four to six times a day for 2 weeks up to 10 
months showed complete remission of itching in 
all 33 patients within 12 days, with doses between 
0.05% and 0.1% being most efficacious (28). The 
downside of capsaicin remains potential non-com-
pliance as a result of the frequency of application 
necessary for treatment success as well as high 
rates of relapse upon discontinuation.  
 As a third line agent, cyclosporine has been 
shown to be beneficial (4). Two patients with se-
vere nodular prurigo were treated with cyclospo-
rine for periods of 24 and 36 weeks, respectively, 
using doses of 3-4.5 mg/kg per day. In both cases 
there was a reduction in the severity of pruritus af-
ter 2 weeks of treatment. In one patient there was 
a considerable, although incomplete, response 
period. In the other almost complete resolution of 
the disease was achieved. The improvement was 
maintained throughout the treatment period. The 
drug was generally well tolerated, although in one 
patient there was a rise in serum creatinine, which 
later returned to normal.
 Thalidomide, which has been used since the 
1970s in the treatment of PN, remains a potent 
third line therapy reserved for severe, recalcitrant 
PN (29). It is thought to act via central nervous 
system suppression and subsequent blockage 
of peripheral stimulation (3). At a dose of 200 
mg daily, significant improvement of pruritus and 
nodular shrinkage with no significant side effects 
has been documented (30). At doses below 200 
mg/day, PN remissions are generally not achieved 
(31). Dosing above 200 mg/day is limited by the 
occurrence of significant adverse effects such as 
sensory neuropathy, which may be irreversible 
(32). The critical dosing level may be even lower 
in patients with HIV. In a prospective study of HIV 
patients with PN, thalidomide dosed between 33 
and 200 mg/day resulted in a 50% reduction in itch 
and skin involvement. However, 1/3 of patients in 
the study developed thalidomide peripheral neu-
ropathy, stressing the importance of frequent neu-
rologic assessment (33).
 Less common experimental treatments for PN 
have been documented; however, their long-term 
efficacy is yet to be determined. Pulsed dye laser 
treatment once a week for 6 weeks offered suc-
cessful treatment for one patient (34). Surgical ex-
cision may be required in some patients (26). 
 We attempt to motivate these patients (Table 4) 
by informing them that 500-1,000 scratches daily 
cause miserable chronicity. We advocate prompt 
use of emollients and topical immunomodulators, 
whether steroids or calcineurin inhibitors. Topical 
pimecrolimus and tacrolimus have demonstrated 
considerable success in the treatment of inflam-
matory skin diseases such as atopic dermatitis, PN 
and neurodermatitis (prurigo simplex), with signifi-
cant improvement of pruritic symptoms (35). Their 
postulated mechanism of action is via inhibition of 
inflammatory cytokines as well as that similar to 
capsaicin. Furthermore, we advocate the applica-
tion of crushed ice prepared to the consistency of 
sherbet for acute intense pruritus. If that does not 
work, we recommend clenching the fist for 30 sec-
onds, then pinching. We tell our patients that itch 
equals healing, if left alone. 
Table 4.  Encouraging prurigo nodularis patients
- Daily 500-1,000 scratches cause miserable chronicity, 
so don’t
- Prompt use of emollients and topical 
immunomodulators
- For acute itch, clench fist for 30 seconds, then pinch 
- Itch = healing, if left alone
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